Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria

Diabetes Research and Clinical Practice

Volumn 103, Issue 3, 2014, Pages 373-381

  Geerlings, Suzanne ^a   Fonseca, Vivian ^b   Castro Diaz, David ^c   List, James ^d   Parikh, Shamik ^e  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^d BRISTOL MYERS SQUIBB   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Genital; Glucosuria; Infections; SGLT2; Type 2 diabetes; Urinary

Indexed keywords

GENITAL; GLUCOSURIA; INFECTIONS; SGLT2; TYPE 2 DIABETES; URINARY;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; GENITAL DISEASES, FEMALE; GENITAL DISEASES, MALE; GLYCOSURIA; HUMANS; HYPOGLYCEMIC AGENTS; MALE; SODIUM-GLUCOSE TRANSPORTER 2; URINARY TRACT INFECTIONS;

EID: 84898917720     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.12.052     Document Type: Review

References (51)

1. Benfield T., Jensen J.S., Nordestgaard B.G. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia 2007, 50(3):549-554.
2. de Leon E.M., Jacober S.J., Sobel J.D., Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis 2002, 21.
3. Nicolle L.E., Bradley S., Colgan R., Rice J.C., Schaeffer A., Hooton T.M. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005, 40(5):643-654. An official publication of the Infectious Diseases Society of America.
4. Ribera M.C., Pascual R., Orozco D., Perez Barba C., Pedrera V., Gil V. Incidence and risk factors associated with urinary tract infection in diabetic patients with and without asymptomatic bacteriuria. Eur J Clin Microbiol Infect Dis 2006, 25(6):389-393.
5. Patterson J.E., Andriole L.E. Bacterial urinary tract infections in diabetes. Infect Dis Clin North Am 1997, 11(3):735-750.
6. Nicolle L.E., Friesen D., Harding G.K., Roos L.L. Hospitalization for acute pyelonephritis in Manitoba, Canada, during the period from 1989 to 1992; impact of diabetes, pregnancy, and aboriginal origin. Clin Infect Dis 1996, 22(6):1051-1056. An official publication of the Infectious Diseases Society of America.
7. Goswami R., Bal C.S., Tejaswi S., Punjabi G.V., Kapil A., Kochupillai N. Prevalence of urinary tract infection and renal scars in patients with diabetes mellitus. Diabetes Res Clin Pract 2001, 53(3):181-186.
8. Zhanel G.G., Harding G.K., Nicolle L.E. Asymptomatic bacteriuria in patients with diabetes mellitus. Rev Infect Dis 1991, 13(1):150-154.
9. Meiland R., Geerlings S.E., Stolk R.P., Netten P.M., Schneeberger P.M., Hoepelman A.I. Asymptomatic bacteriuria in women with diabetes mellitus: effect on renal function after 6 years of follow-up. Arch Intern Med 2006, 166(20):2222-2227.
10. Renko M., Tapanainen P., Tossavainen P., Pokka T., Uhari M. Meta-analysis of the significance of asymptomatic bacteriuria in diabetes. Diabetes Care 2011, 34(1):230-235.
11. Hirji I., Guo Z., Andersson S.W., Hammar N., Gomez-Caminero A. Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD). J Diabetes Complicat 2012, 26(6):513-516.
12. Janifer J., Geethalakshmi S., Satyavani K., Viswanathan V. Prevalence of lower urinary tract infection in South Indian type 2 diabetic subjects. Indian J Nephrol 2009, 19(3):107-111.
13. Hakeem M.H., Bhattacharyya D.N., Lafong C., Janjua K.S., Serhan J.T., Campbell I.W. Diversity and complexity of urinary tract infection in diabetes mellitus. Br J Diabetes Vasc Dis 2009, 9(3):119-125.
14. Carton J.A., Maradona J.A., Nuno F.J., Fernandez-Alvarez R., Perez-Gonzalez F., Asensi V. Diabetes mellitus and bacteraemia: a comparative study between diabetic and non-diabetic patients. Eur J Med 1992, 1(5):281-287.
15. Geerlings S.E., Brouwer E.C., Gaastra W., Verhoef J., Hoepelman A.I. Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli: studies with urine from diabetic and non-diabetic individuals. J Med Microbiol 1999, 48(6):535-539.
16. Turan H., Serefhanoglu K., Torun A.N., Kulaksizoglu S., Kulaksizoglu M., Pamuk B., et al. Frequency, risk factors, and responsible pathogenic microorganisms of asymptomatic bacteriuria in patients with type 2 diabetes mellitus. Jpn J Infect Dis 2008, 61(3):236-238.
17. Geerlings S.E., Stolk R.P., Camps M.J., Netten P.M., Hoekstra J.B., Bouter P.K., et al. Asymptomatic bacteriuria may be considered a complication in women with diabetes. Diabetes Mellitus Women Asymptomatic Bacteriuria Utrecht Study Group. Diabetes Care 2000, 23(6):744-749.
18. Geerlings S.E., Stolk R.P., Camps M.J., Netten P.M., Collet T.J., Hoepelman A.I. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 2000, 23(12):1737-1741.
19. Geerlings S.E., Meiland R., van Lith E.C., Brouwer E.C., Gaastra W., Hoepelman A.I. Adherence of type 1-fimbriated Escherichia coli to uroepithelial cells: more in diabetic women than in control subjects. Diabetes Care 2002, 25(8):1405-1409.
20. Wu X.R., Sun T.T., Medina J.J. In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. PNAS 1996, 93(18):9630-9635.
21. Delamaire M., Maugendre D., Moreno M., Le Goff M.C., Allannic H., Genetet B. Impaired leucocyte functions in diabetic patients. Diabetic Med 1997, 14(1):29-34.
22. Geerlings S.E., Brouwer E.C., Van Kessel K.C., Gaastra W., Stolk R.P., Hoepelman A.I. Cytokine secretion is impaired in women with diabetes mellitus. Eur J Clin Invest 2000, 30(11):995-1001.
23. Hoepelman A.I., Meiland R., Geerlings S.E. Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents 2003, 22(Suppl):235-243.
24. Grigoriou O., Baka S., Makrakis E., Hassiakos D., Kapparos G., Kouskouni E. Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol 2006, 126(1):121-125.
25. Hirji I., Andersson S.W., Guo Z., Hammar N., Gomez-Caminero A. Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database. J Diabetes Complicat 2012, 26(6):501-505.
26. Goswami R., Dadhwal V., Tejaswi S., Datta K., Paul A., Haricharan R.N., et al. Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. J Infect 2000, 41(2):162-166.
27. Wilson R.M., Tomlinson D.R., Reeves W.G. Neutrophil sorbitol production impairs oxidative killing in diabetes. Diabetic Med 1987, 4(1):37-40.
28. Hostetter M.K. Handicaps to host defense. Effects of hyperglycemia on C3 and Candida albicans. Diabetes 1990, 39(3):271-275.
29. Segal E., Soroka A., Schechter A. Correlative relationship between adherence of Candida albicans to human vaginal epithelial cells in vitro and candidal vaginitis. Sabouraudia 1984, 22(3):191-200.
30. Komoroski B., Vachharajani N., Feng Y., Li L., Kornhauser D., Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009, 85(5):513-519.
31. List J.F., Woo V., Morales E., Tang W., Fiedorek F.T. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009, 32(4):650-657.
32. Bailey C., Gross J., Hennicken D., Iqbal N., Mansfield T., List J.F. Long-term efficacy of dapagliflozin as add-on to metformin in T2DM inadequately controlled with metformin alone. 71st scientific sessions of the American Diabetes Association (ADA) 2011.
33. Parikh S.J., Johnsson K.M., Ptaszynska A., Schmitz B., Sugg J., List J.F. Characterization of urinary tract infections in the setting of pharmacologically-induced glucosuria. 71st scientific sessions of the American Diabetes Association (ADA) 2011.
34. Ferrannini E., Ramos S.J., Salsali A., Tang W., List J.F. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010, 33(10):2217-2224.
35. Bailey C.J., Gross J.L., Pieters A., Bastien A., List J.F. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375(9733):2223-2233.
36. Strojek K., Yoon K.H., Hruba V., Elze M., Langkilde A.M., Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes, Obes Metab 2011, 13(10):928-938.
37. Wilding J.P., Woo V., Soler N.G., Pahor A., Sugg J., Parikh S. Dapagliflozin in patients with type 2 diabetes poorly controlled on insulin therapy-efficacy of a novel insulin-independent treatment. Presented at the 70th sessions of the American Diabetes Association 2010.
38. Rosenstock J., Vico M., Wei L., Salsali A., List J.F. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012, 35(7):1473-1478.
39. Kaku K., Inoue S., Matsuoka O., Kiyosue A., Azuma H., Hayashi N., et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes, Obes Metab 2013, 15(5):432-440.
40. Bailey C.J., Iqbal N., T'Joen C., List J.F. Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes, Obes Metab 2012, 14(10):951-959.
41. Wilding J.P., Norwood P., T'Joen C., Bastien A., List J.F., Fiedorek F.T. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009, 32(9):1656-1662.
42. Henry R.R., Murray A.V., Marmolejo M.H., Hennicken D., Ptaszynska A., List J.F. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012, 66(5):446-456.
43. Bolinder J., Ljunggren Ö., Kullberg J., Johansson L., Wilding J., Langkilde A.M., et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012, 97(3):1020-1031.
44. List J.F., Ley S., Ptaszynska A., Johnsson K.M., Schmitz B.G., Sugg J.E., et al. Characterization of genital infections in the setting of pharmacologically-induced glucosuria. American Diabetes Association (ADA) 71st scientific sessions 2011.
45. Nicolle L.E., Capuano G., Ways K., Usiskin K. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin 2012, 28(7):1167-1171.
46. Nyirjesy P., Zhao Y., Ways K., Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012, 28(7):1173-1178.
47. Cefalu W.T., Leiter L.A., Yoon K.H., Arias P., Niskanen L., Xie J., et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013, 382(9896):941-950.
48. Schernthaner G., Gross J.L., Rosenstock J., Guarisco M., Fu M., Yee J., et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013, 36(9):2508-2515.
49. Ferrannini E., Seman L., Seewaldt-Becker E., Hantel S., Pinnetti S., Woerle H.J. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes, Obes Metab 2013.
50. Rosenstock J., Seman L.J., Jelaska A., Hantel S., Pinnetti S., Hach T., et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013, 15(12):1154-1160.
51. Schwartz S.L., Akinlade B., Klasen S., Kowalski D., Zhang W., Wilpshaar W. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2011, 13(12):1219-1227.